Barclays
KZR

Barclays’s Kezar Life Sciences KZR Stock Holding History

Barclays’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7 Hold
1
– – ﹤0.01% 4985
2025
Q4 		$6 Hold
1
– – ﹤0.01% 5161
2025
Q3 		$4 Hold
1
– – ﹤0.01% 5418
2025
Q2 		$5 Hold
1
– – ﹤0.01% 5170
2025
Q1 		$5 Hold
1
– – ﹤0.01% 5192
2024
Q4 		$7 Buy
+1
New +$7 ﹤0.01% 5230
2024
Q3 		– Sell
-22
Closed -$133 – 5262
2024
Q2 		$131 Sell
22
-4,990
-100% -$37.9K ﹤0.01% 4747
2024
Q1 		$45.2K Sell
5,012
-4,792
-49% -$43.7K ﹤0.01% 4633
2023
Q4 		$92.9K Buy
9,804
+8,545
+679% +$75.1K ﹤0.01% 4653
2023
Q3 		$15K Sell
1,259
-164
-12% -$2.91K ﹤0.01% 4231
2023
Q2 		$34.9K Sell
1,423
-81,480
-98% -$2.12M ﹤0.01% 3985
2023
Q1 		$2.59M Buy
82,903
+64,154
+342% +$3.71M ﹤0.01% 1997
2022
Q4 		$1.32M Buy
18,749
+3,428
+22% +$254K ﹤0.01% 2577
2022
Q3 		$1.32M Buy
15,321
+14,918
+3,702% +$1.45M ﹤0.01% 2027
2022
Q2 		$33K Sell
403
-212
-34% -$18.7K ﹤0.01% 4206
2022
Q1 		$102K Sell
615
-3,631
-86% -$521K ﹤0.01% 3771
2021
Q4 		$710K Buy
4,246
+1,046
+33% +$118K ﹤0.01% 3023
2021
Q3 		$277K Buy
3,200
+961
+43% +$63.6K ﹤0.01% 3456
2021
Q2 		$122K Sell
2,239
-2,199
-50% -$125K ﹤0.01% 3769
2021
Q1 		$264K Buy
4,438
+1,607
+57% +$93.9K ﹤0.01% 3576
2020
Q4 		$148K Sell
2,831
-381
-12% -$21.2K ﹤0.01% 3944
2020
Q3 		$155K Sell
3,212
-180
-5% -$8.61K ﹤0.01% 4013
2020
Q2 		$175K Buy
3,392
+561
+20% +$28.3K ﹤0.01% 4164
2020
Q1 		$124K Sell
2,831
-550
-16% -$22.4K ﹤0.01% 4647
2019
Q4 		$135K Buy
3,381
+787
+30% +$24.2K ﹤0.01% 5296
2019
Q3 		$85K Buy
2,594
+90
+4% +$4.34K ﹤0.01% 5596
2019
Q2 		$193K Buy
2,504
+2,148
+603% +$334K ﹤0.01% 5138
2019
Q1 		$63K Buy
+356
New +$70.2K ﹤0.01% 5707
2018
Q4 		– Sell
-193
Closed -$41K – 7135
2018
Q3 		$41K Buy
+193
New +$33.7K ﹤0.01% 6187

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Barclays's KZR Position: Q1 2026 in Review

Barclays held its Kezar Life Sciences (KZR) position steady in Q1 2026 at 1 share worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #4985.

Barclays first reported a position in KZR in Q3 2018 and has held it in 29 quarters since. The position peaked at $2.59M in Q1 2023. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Barclays held 1 share of Kezar Life Sciences worth $7 as of Q1 2026.
  • Barclays left its Kezar Life Sciences share count unchanged in Q1 2026.
  • Kezar Life Sciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4985 holding.
  • Barclays first reported a position in Kezar Life Sciences in Q3 2018 and has held it in 29 quarters since.
  • Barclays's Kezar Life Sciences position peaked at $2.59M in Q1 2023.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.